Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Venetoclax is a novel BCL-2 inhibitor that induces apoptosis in cancer cells by ···【more】
Release date：2024-08-14Recommended：276
Venetoclax is the world's only approved selective inhibitor of Bcl-2 that ca···【more】
Release date：2024-08-14Recommended：292
Venetoclax restores normal apoptosis of cancer cells by blocking the anti-apopto···【more】
Release date：2024-08-14Recommended：330
Venetoclax is the only approved inhibitor of Bcl-2, which achieves high selectiv···【more】
Release date：2024-08-14Recommended：288
Venetoclax is an oral, small-molecule targeted drug that restores the apoptosis ···【more】
Release date：2024-08-14Recommended：322
Venetoclax is the world's first approved selective inhibitor of Bcl-2 that i···【more】
Release date：2024-08-14Recommended：330
Pemigatinib is a targeted therapy drug that is of great significance in the trea···【more】
Release date：2024-08-14Recommended：283
Pemigatinibis primarily used for the treatment of adult patients with advanced, ···【more】
Release date：2024-08-14Recommended：275
Pemigatinibhas demonstrated significant efficacy in the treatment of cholangioca···【more】
Release date：2024-08-14Recommended：304
Pemigatinib is used in adults to treat bile duct cancer that has spread to other···【more】
Release date：2024-08-14Recommended：276
Pemigatinib is an effective treatment for advanced or metastatic cholangiocarcin···【more】
Release date：2024-08-14Recommended：264
Pemigatinib leads to constitutive activation of FGFR by activating FGFR amplific···【more】
Release date：2024-08-14Recommended：280
